Show simple item record

dc.contributor.authorDoyon, Anke
dc.contributor.authorFischer, Dagmar-Christiane
dc.contributor.authorBayazit, Aysun Karabay
dc.contributor.authorCanpolat, Nur
dc.contributor.authorDuzova, Ali
dc.contributor.authorSözeri, Betül
dc.contributor.authorBacchetta, Justine
dc.contributor.authorBalat, Ayse
dc.contributor.authorBüscher, Anja
dc.contributor.authorCandan, Cengiz
dc.contributor.authorCakar, Nilgun
dc.contributor.authorDonmez, Osman
dc.contributor.authorDusek, Jiri
dc.contributor.authorHeckel, Martina
dc.contributor.authorKlaus, Günter
dc.contributor.authorMir, Sevgi
dc.contributor.authorÖzcelik, Gül
dc.contributor.authorSever, Lale
dc.contributor.authorShroff, Rukshana
dc.contributor.authorVidal, Enrico
dc.contributor.authorWühl, Elke
dc.contributor.authorGondan, Matthias
dc.contributor.authorMelk, Anette
dc.contributor.authorQuerfeld, Uwe
dc.contributor.authorHaffner, Dieter
dc.contributor.authorSchaefer, Franz
dc.date.accessioned2019-12-10T10:40:31Z
dc.date.available2019-12-10T10:40:31Z
dc.date.issued2015
dc.identifier.issn1932-6203
dc.identifier.urihttps://doi.org/10.1371/journal.pone.0113482
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319910/
dc.identifier.urihttp://hdl.handle.net/11655/14150
dc.description.abstractObjectives The extent and relevance of altered bone metabolism for statural growth in children with chronic kidney disease is controversial. We analyzed the impact of renal dysfunction and recombinant growth hormone therapy on a panel of serum markers of bone metabolism in a large pediatric chronic kidney disease cohort. Methods Bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRAP5b), sclerostin and C-terminal FGF-23 (cFGF23) normalized for age and sex were analyzed in 556 children aged 6–18 years with an estimated glomerular filtration rate (eGFR) of 10–60 ml/min/1.73m2. 41 children receiving recombinant growth hormone therapy were compared to an untreated matched control group. Results Standardized levels of BAP, TRAP5b and cFGF-23 were increased whereas sclerostin was reduced. BAP was correlated positively and cFGF-23 inversely with eGFR. Intact serum parathormone was an independent positive predictor of BAP and TRAP5b and negatively associated with sclerostin. BAP and TRAP5B were negatively affected by increased C-reactive protein levels. In children receiving recombinant growth hormone, BAP was higher and TRAP5b lower than in untreated controls. Sclerostin levels were in the normal range and higher than in untreated controls. Serum sclerostin and cFGF-23 independently predicted height standard deviation score, and BAP and TRAP5b the prospective change in height standard deviation score. Conclusion Markers of bone metabolism indicate a high-bone turnover state in children with chronic kidney disease. Growth hormone induces an osteoanabolic pattern and normalizes osteocyte activity. The osteocyte markers cFGF23 and sclerostin are associated with standardized height, and the markers of bone turnover predict height velocity.
dc.relation.isversionof10.1371/journal.pone.0113482
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleMarkers of Bone Metabolism Are Affected by Renal Function and Growth Hormone Therapy in Children with Chronic Kidney Disease
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalPLoS ONE
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları
dc.identifier.volume10
dc.identifier.issue2
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Files in this item

This item appears in the following Collection(s)

Show simple item record